Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) shares have a current ABR (average broker recommendation) of N/A. This recommendation is offered by Zacks Research. The rating lands on a sliding numerical scale from 1 to 5. A recommendation of 5 would indicate a Strong Sell, and a 1 would signify a Strong Buy. The mean rating may help provide a general sense of analyst sentiment on company shares.
Sell-side analysts taken into consideration by Zacks have also provided price target estimates on shares of Carrizo Oil & Gas, Inc. (NASDAQ:CRZO). The highest current target is $N/A. The lowest price target out of the polled analysts is presently $N/A. The consensus target price is currently noted at $N/A. Analysts may employ various techniques to help predict future stock price levels.
On the earnings front, Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) is expected to post quarterly earnings per share of $N/A. This is the current consensus figure provided by Zacks. Investors and analysts will be looking for the company to next post earnings on or around N/A. Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) most recently reported quarterly EPS of $N/A for the quarter ending N/A. The gap between the actual and the projected estimate leading up to earnings created a surprise factor of N/A%.
Research analysts covering Valeant Pharmaceuticals International, Inc. (NYSE:VRX) are projecting that the shares reach $N/A within the next 12-18 months. This is the consensus number derived from the N/A analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $N/A, while the most bearish, or conservative analyst sees the stock reaching $N/A.
Broker Rating Update on Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) currently have an ABR of N/A. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $N/A earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.
taking a look at the most recent period, which closed on N/A, Valeant Pharmaceuticals International, Inc. reported EPS of $N/A for a surprise factor of N/A%, calculated by being $N/A away from analyst projections.
Investors will be marking their calendars for N/A, when the company is planning to release their quarterly results.